Advances in genetics has altered the landscape for newborn screening, giving families new hope of detecting disease -- particularly rare disease -- earlier than ever. Embracing the new reality will increase opportunities for new and existing therapies, and the number of lives to save or improve seems limitless. However, major obstacles await forces of change: an antiquated and patchwork government system for approving newborn screening, major gaps in parental education, a public health infrastructure under constant stress, and shortage of geneticists.

With Congress currently considering changes to the Newborn Screening Saves Lives Act, explore how the biotechnology community can work with our partners today and tomorrow to help fulfill the promise for patients in this new, existing era.

Ability Level: Intermediate

Session ID: 503410